We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Non-Invasive COVID-19 Diagnostic System Collects Sample Droplets from Lungs and Returns Results in 10 Minutes

By LabMedica International staff writers
Posted on 22 Jul 2021
Print article
Image: Novel BlowFISH device that captures virus within Exhaled Breath Condensate (EBC) (Photo courtesy of Medivolve Inc.)
Image: Novel BlowFISH device that captures virus within Exhaled Breath Condensate (EBC) (Photo courtesy of Medivolve Inc.)
A non-invasive exhaled breath diagnostic technology offers the potential for a simple, inexpensive, non-invasive, massively deployable, rapid diagnostic system for detecting respiratory illness and airborne viral threats, including COVID-19, in approximately 10 minutes.

The non-invasive exhaled breath diagnostic technology, BlowFISH, developed by Marvel Diagnostics Inc. based at University of California (Los Angeles, CA, USA) and funded by Medivolve Inc. (Toronto, Canada) has successfully cleared the first milestone in a series of clinical tests targeting application of an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) to test for the COVID-19 virus. During the clinical trial, BlowFISH’s proprietary technology, designed to efficiently collect a substantial liquid sampling directly from deep within the lungs, successfully detected the COVID-19 virus in three test samples.

“This is an exciting and important milestone in advancing BlowFISH toward achieving EUA status in testing for COVID-19, and providing a non-invasive, cost-effective and scalable testing alternative to nasal swab solutions currently in market," said David Preiner, CEO, Medivolve. “Making testing more accessible to populations, such as children and the elderly, where it may be difficult to administer a nasopharyngeal swab test, will become important in our transition to resuming daily life in the 'new normal'.”

“BlowFISH’s detection of the COVID-19 virus brings us one significant step closer to changing the future of diagnostics for not only COVID-19, but for a wide range of respiratory illnesses,” said Dr. Pirouz Kavehpour, UCLA Professor and Marvel Diagnostics Co-Founder. “We are moving forward with urgency through proof-of-concept clinical trials, as these studies are a critical next step in making respiratory testing more comfortable, convenient and accessible for all...one breath at a time.”

Related Links:
Medivolve Inc.

New
Gold Supplier
COVID-19 TEST READER
COVID-19-CHECK-1 EASY READER+
New
SARS-CoV-2 LAMP Test
SARS-CoV-2 LAMP Solution
New
Automated Immunoassay Analyzer
Maverick Diagnostic System (MDS)
New
PCR System
Biomark HD

Print article

Channels

Molecular Diagnostics

view channel
Image: Primary angle closure glaucoma can cause permanent blindness if not treated quickly. A highly sensitive genetic test has been developed (Photo courtesy of Flinders University)

Highly Sensitive Genetic Test for Glaucoma Developed

In open-angle glaucoma, the angle in the eye where the iris meets the cornea is as wide and open as it should be, but the eye’s drainage canals become clogged over time, causing an increase in internal... Read more

Industry

view channel
Illustration

ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC

ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders. The acquisition will also provides the industry with a full range of osmometry solutions... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.